|
KR100508289B1
(ko)
*
|
1998-04-21 |
2005-08-17 |
마이크로메트 에이지 |
Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
|
|
JP3425536B2
(ja)
|
1999-04-21 |
2003-07-14 |
株式会社チップトン |
コーティング装置
|
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
|
DE10254601A1
(de)
|
2002-11-22 |
2004-06-03 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
|
ZA200601699B
(en)
*
|
2003-10-16 |
2007-05-30 |
Micromet Ag |
Multispecific deimmunized CD3-binders
|
|
BRPI0507649A
(pt)
|
2004-02-16 |
2007-07-10 |
Micromet Ag |
molécula de ligação biespecìfica, seqüência de ácido nucléico, vetor, processo para a produção da molécula de ligação biespecìfica, composição, uso da molécula de ligação biespecìfica na preparação da composição farmacêutica, e kit
|
|
EP1774017B1
(en)
|
2004-07-26 |
2013-05-15 |
Pfenex Inc. |
Process for improved protein expression by strain engineering
|
|
ES2417065T3
(es)
|
2005-04-26 |
2013-08-05 |
Trion Pharma Gmbh |
Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer
|
|
CN103146708A
(zh)
|
2005-06-30 |
2013-06-12 |
Abbvie公司 |
Il-12/p40结合蛋白
|
|
JP5686953B2
(ja)
|
2005-10-11 |
2015-03-18 |
アムゲン リサーチ （ミュンヘン） ゲーエムベーハー |
交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
|
|
SI1976886T1
(sl)
*
|
2005-12-16 |
2015-03-31 |
Amgen Research (Munich) Gmbh |
Sredstva in postopki za zdravljenje tumorskih bolezni
|
|
AU2013202375B2
(en)
*
|
2005-12-16 |
2016-10-27 |
Amgen Research (Munich) Gmbh |
Means and Methods for the Treatment of Tumorous Diseases
|
|
PL2383297T3
(pl)
*
|
2006-08-14 |
2013-06-28 |
Xencor Inc |
Zoptymalizowane przeciwciała ukierunkowane na CD19
|
|
JP5401314B2
(ja)
*
|
2006-09-08 |
2014-01-29 |
メディミューン，エルエルシー |
ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用
|
|
PL3339445T3
(pl)
|
2006-09-08 |
2020-12-14 |
Abbvie Bahamas Ltd. |
Białka wiążące interleukinę 13
|
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
US9394571B2
(en)
|
2007-04-27 |
2016-07-19 |
Pfenex Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
EP2014680A1
(en)
*
|
2007-07-10 |
2009-01-14 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
|
|
WO2009052431A2
(en)
*
|
2007-10-19 |
2009-04-23 |
Seattle Genetics, Inc. |
Cd19 binding agents and uses thereof
|
|
WO2009070642A1
(en)
*
|
2007-11-28 |
2009-06-04 |
Medimmune, Llc |
Protein formulation
|
|
JP5646457B2
(ja)
*
|
2008-04-29 |
2014-12-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
PE20100054A1
(es)
*
|
2008-06-03 |
2010-03-03 |
Abbott Lab |
Inmunoglobulina con dominio variable dual
|
|
EP3002299A1
(en)
|
2008-06-03 |
2016-04-06 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
MX2010014574A
(es)
*
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
|
EP2700651B1
(en)
|
2008-07-18 |
2019-04-10 |
Bristol-Myers Squibb Company |
Compositions monovalent for CD28 binding and methods of use
|
|
SG194399A1
(en)
*
|
2008-10-01 |
2013-11-29 |
Amgen Res Munich Gmbh |
Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
|
|
EP4180458A1
(en)
*
|
2008-10-01 |
2023-05-17 |
Amgen Research (Munich) GmbH |
Cross-species-specific psma x cd3 bispecific single chain antibody
|
|
CA2738568C
(en)
|
2008-10-01 |
2024-02-20 |
Micromet Ag |
Cross-species-specific single domain bispecific single chain antibody
|
|
DK2352763T4
(da)
|
2008-10-01 |
2022-10-17 |
Amgen Res Munich Gmbh |
Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
|
|
TW201109438A
(en)
*
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
AR078254A1
(es)
*
|
2009-09-01 |
2011-10-26 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
MX2012004415A
(es)
*
|
2009-10-15 |
2012-05-08 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
|
BR112012009778A2
(pt)
|
2009-10-27 |
2017-06-13 |
Micromet Ag |
regime de dosagem para administrar um anticorpo biespecífico de cd19xcd3
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
SI2519543T1
(sl)
|
2009-12-29 |
2016-08-31 |
Emergent Product Development Seattle, Llc |
Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
|
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
|
CN102250245B
(zh)
*
|
2010-05-27 |
2014-05-14 |
四川大学 |
抗b细胞淋巴瘤的双特异性抗体及其用途
|
|
EP2409712A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
|
|
EP2409993A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC function with improved glycosylation profile
|
|
CA2806252C
(en)
|
2010-07-29 |
2019-05-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
US8735546B2
(en)
|
2010-08-03 |
2014-05-27 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
PH12013500337A1
(en)
|
2010-08-26 |
2017-08-23 |
Abbvie Inc |
Dual variable domain immunoglobulins and uses thereof
|
|
KR101584416B1
(ko)
|
2010-10-05 |
2016-01-13 |
에프. 호프만-라 로슈 아게 |
인간 tweak에 대한 항체 및 그의 용도
|
|
KR101889995B1
(ko)
|
2010-10-27 |
2018-08-20 |
암젠 리서치 (뮌헨) 게엠베하 |
Dlbcl의 치료 수단 및 방법
|
|
PL2635607T3
(pl)
|
2010-11-05 |
2020-05-18 |
Zymeworks Inc. |
Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
|
|
SMT201700250T1
(it)
|
2010-11-10 |
2017-07-18 |
Amgen Res Munich Gmbh |
Prevenzione di effetti avversi provocati da domini leganti cd3 specifici
|
|
US20130273055A1
(en)
*
|
2010-11-16 |
2013-10-17 |
Eric Borges |
Agents and methods for treating diseases that correlate with bcma expression
|
|
US20140056897A1
(en)
|
2011-03-10 |
2014-02-27 |
Hco Antibody, Inc. |
Bispecific three-chain antibody-like molecules
|
|
EP2701741B1
(en)
|
2011-04-28 |
2020-06-10 |
Amgen Research (Munich) GmbH |
Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
|
|
US9587021B2
(en)
*
|
2011-05-21 |
2017-03-07 |
Macrogenics, Inc. |
CD3-binding molecules capable of binding to human and non-human CD3
|
|
CA2850291A1
(en)
*
|
2011-09-29 |
2013-04-04 |
Apo-T B.V. |
Multi-specific binding molecules targeting aberrant cells
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
PL2773671T3
(pl)
|
2011-11-04 |
2022-01-24 |
Zymeworks Inc. |
Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
BR112014016085A8
(pt)
|
2011-12-28 |
2017-07-04 |
Pozen Inc |
composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
|
|
US9120870B2
(en)
|
2011-12-30 |
2015-09-01 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-13 and IL-17
|
|
US10946104B2
(en)
|
2012-01-13 |
2021-03-16 |
Apo-Tb.V. |
Aberrant cell-restricted immunoglobulins provided with a toxic moiety
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
KR20150004856A
(ko)
|
2012-04-20 |
2015-01-13 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
Cd3 결합 폴리펩타이드
|
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
AU2013289971A1
(en)
|
2012-07-13 |
2015-01-22 |
The Trustees Of The University Of Pennsylvania |
Enhancing activity of CAR T cells by co-introducing a bispecific antibody
|
|
AU2013337775B2
(en)
|
2012-11-01 |
2017-03-30 |
Abbvie Inc. |
Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
|
|
CN105073776B
(zh)
*
|
2012-11-13 |
2019-04-12 |
拜恩科技股份公司 |
用于治疗表达紧密连接蛋白的癌症疾病的制剂
|
|
WO2014079000A1
(en)
*
|
2012-11-21 |
2014-05-30 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
CA2898100C
(en)
|
2013-01-14 |
2023-10-10 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
CA2897987A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
US9486475B2
(en)
|
2013-02-08 |
2016-11-08 |
Amgen Research (Munich) Gmbh |
PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
|
|
JO3529B1
(ar)
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2970459A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Dual specific binding proteins directed against il-1beta and il-17
|
|
US20140302037A1
(en)
*
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CN104342453A
(zh)
*
|
2013-08-06 |
2015-02-11 |
深圳先进技术研究院 |
含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
|
|
ES2764833T3
(es)
|
2013-10-11 |
2020-06-04 |
The United States Of America Represented By The Sec Dep Of Health And Human Services |
Anticuerpos contra TEM8 y su uso
|
|
EP4570318A3
(en)
|
2013-11-27 |
2025-10-15 |
Zymeworks BC Inc. |
Bispecific antigen-binding constructs targeting her2
|
|
BR112016013741A2
(pt)
|
2013-12-17 |
2017-10-03 |
Genentech Inc |
Usos de antagonistas de ligação de eixo de pd-1 e um anticorpo de anti-cd20, e kit compreendendo os mesmos
|
|
SG10202002334PA
(en)
|
2013-12-17 |
2020-05-28 |
Genentech Inc |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
US20160326249A1
(en)
*
|
2014-01-15 |
2016-11-10 |
Zymeworks Inc. |
Bi-specific cd3 and cd19 antigen-binding constructs
|
|
WO2015121383A1
(en)
|
2014-02-12 |
2015-08-20 |
Michael Uhlin |
Bispecific antibodies for use in stem cell transplantation
|
|
JP6775422B2
(ja)
|
2014-03-28 |
2020-10-28 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
|
|
CN105017422A
(zh)
*
|
2014-04-30 |
2015-11-04 |
山东百因制药技术有限公司 |
一种抗cd3/抗cd19双特异性抗体及其应用
|
|
FI3531133T3
(fi)
|
2014-05-30 |
2023-11-02 |
Amgen Res Munich Gmbh |
Prekursori-b-solujen akuutin lymfoblastisen leukemian potilaiden riskiluokittelu
|
|
KR20170010863A
(ko)
|
2014-07-01 |
2017-02-01 |
화이자 인코포레이티드 |
이중특이성 이종이량체성 디아바디 및 이의 용도
|
|
MY181834A
(en)
|
2014-07-21 |
2021-01-08 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
JP6736540B2
(ja)
|
2014-07-21 |
2020-08-05 |
ノバルティス アーゲー |
Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置
|
|
US9611325B2
(en)
|
2014-07-21 |
2017-04-04 |
Wuhan Yzy Biopharma Co., Ltd. |
Construction and application of bispecific antibody HER2xCD3
|
|
WO2016036678A1
(en)
*
|
2014-09-02 |
2016-03-10 |
Medimmune, Llc |
Formulations of bispecific antibodies
|
|
HRP20201351T1
(hr)
|
2014-11-05 |
2020-11-27 |
Genentech, Inc. |
Postupci proizvodnje dvolančanih proteina u bakteriji
|
|
AU2015342961B2
(en)
|
2014-11-05 |
2021-08-12 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
|
WO2016077789A1
(en)
|
2014-11-14 |
2016-05-19 |
The Usa, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
|
SG11201704283PA
(en)
|
2014-11-26 |
2017-06-29 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
JP2017536830A
(ja)
|
2014-11-26 |
2017-12-14 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３及びｃｄ３８に結合するヘテロ二量体抗体
|
|
EP3029067A1
(en)
|
2014-12-01 |
2016-06-08 |
Deutsches Krebsforschungszentrum |
Use of blocking-reagents for reducing unspecific T cell-activation
|
|
AR102918A1
(es)
*
|
2014-12-05 |
2017-04-05 |
Genentech Inc |
Anticuerpos anti-cd79b y métodos de uso
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
IL301458A
(en)
*
|
2014-12-24 |
2023-05-01 |
Autolus Ltd |
A cell that simultaneously expresses a chimeric antigen receptor (CAR) of 19CD and 22CD
|
|
CN104592393B
(zh)
*
|
2015-01-21 |
2018-09-28 |
武汉友芝友生物制药有限公司 |
一种双特异性抗体cd19×cd3的构建及应用
|
|
CN107635578A
(zh)
*
|
2015-02-05 |
2018-01-26 |
Stc.Unm 公司 |
抗前‑bcr拮抗剂和方法
|
|
US10301377B2
(en)
|
2015-02-24 |
2019-05-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
|
CA2977687C
(en)
|
2015-02-24 |
2024-02-13 |
Hwai Wen Chang |
Conditionally active proteins
|
|
CA2977271A1
(en)
|
2015-03-02 |
2016-09-09 |
Synthetic Genomics, Inc. |
Regulatory elements from labyrinthulomycetes microorganisms
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
SMT202000255T1
(it)
|
2015-03-20 |
2020-07-08 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services |
Anticorpi neutralizzanti diretti contro gp120 e loro utilizzo
|
|
AU2016256911B2
(en)
|
2015-05-07 |
2022-03-31 |
Agenus Inc. |
Anti-OX40 antibodies and methods of use thereof
|
|
MX383614B
(es)
*
|
2015-05-21 |
2025-03-14 |
Harpoon Therapeutics Inc |
Proteinas de union triespecificas y metodos de uso.
|
|
ES2810700T3
(es)
|
2015-05-29 |
2021-03-09 |
Hoffmann La Roche |
Metilación del promotor de PD-L1 en cáncer
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
CA2986263A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
|
CA2991799A1
(en)
|
2015-07-15 |
2017-01-19 |
Zymeworks Inc. |
Drug-conjugated bi-specific antigen-binding constructs
|
|
TWI796283B
(zh)
*
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI717375B
(zh)
*
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
ES2980794T3
(es)
|
2015-09-15 |
2024-10-03 |
Acerta Pharma Bv |
Combinaciones terapéuticas de un inhibidor de CD19 y un inhibidor de BTK
|
|
KR102784293B1
(ko)
|
2015-09-21 |
2025-03-20 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
Cd3 결합 폴리펩타이드
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
CN108026177B
(zh)
|
2015-10-02 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
双特异性抗cd19xcd3 t细胞活化性抗原结合分子
|
|
CA2997809A1
(en)
|
2015-10-07 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
|
|
CA3003878A1
(en)
|
2015-11-03 |
2017-05-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 gp41 and their use
|
|
SG10201912984WA
(en)
|
2015-12-02 |
2020-03-30 |
Agenus Inc |
Antibodies and methods of use thereof
|
|
TW201720458A
(zh)
*
|
2015-12-04 |
2017-06-16 |
宏觀基因股份有限公司 |
能夠結合cd19 和cd3 的雙特異性單價雙抗體以及其用途
|
|
JP7058219B2
(ja)
|
2015-12-07 |
2022-04-21 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
|
|
AU2016368469B2
(en)
|
2015-12-09 |
2023-11-02 |
F. Hoffmann-La Roche Ag |
Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
JP6955507B2
(ja)
|
2015-12-14 |
2021-10-27 |
マクロジェニクス，インコーポレーテッド |
Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
|
|
AR107303A1
(es)
|
2016-01-08 |
2018-04-18 |
Hoffmann La Roche |
Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
|
|
JOP20170017B1
(ar)
*
|
2016-01-25 |
2021-08-17 |
Amgen Res Munich Gmbh |
تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
|
|
TW202302631A
(zh)
*
|
2016-03-08 |
2023-01-16 |
日商武田藥品工業股份有限公司 |
可誘導性結合蛋白和使用方法
|
|
US12128102B2
(en)
|
2016-03-08 |
2024-10-29 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
EP3430035A4
(en)
*
|
2016-03-16 |
2020-02-19 |
Conagen Inc. |
PRODUCTION OF PROTEINS IN LABYRINE THULOMYCETES
|
|
SG11201809316XA
(en)
*
|
2016-04-28 |
2018-11-29 |
Biomunex Pharmaceuticals |
Bispecific antibodies targeting egfr and her2
|
|
WO2017192589A1
(en)
|
2016-05-02 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to influenza ha and their use and identification
|
|
CN107365387B
(zh)
*
|
2016-05-12 |
2022-03-15 |
阿思科力(苏州)生物科技有限公司 |
一种双特异性抗原结合构建体及其制备方法和应用
|
|
US11339225B2
(en)
|
2016-05-12 |
2022-05-24 |
Asclepius (Suzhou) Technology Company Group, Co., Ltd. |
Bispecific antigen-binding construct and preparation method and use thereof
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
CN110603266A
(zh)
|
2016-06-02 |
2019-12-20 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
|
|
MA45255A
(fr)
|
2016-06-14 |
2019-04-17 |
Xencor Inc |
Anticorps inhibiteurs de points de contrôle bispécifiques
|
|
CN109641049B
(zh)
|
2016-06-21 |
2023-07-07 |
特尼奥生物股份有限公司 |
Cd3结合抗体
|
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
|
AU2017291262A1
(en)
*
|
2016-06-30 |
2019-01-03 |
F. Hoffmann-La Roche Ag |
Improved adoptive T-cell therapy
|
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
|
JP7250674B2
(ja)
|
2016-08-08 |
2023-04-03 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療及び診断方法
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
MY200988A
(en)
|
2016-09-14 |
2024-01-27 |
Teneobio Inc |
CD3 Binding Antibodies
|
|
BR112019007281A2
(pt)
|
2016-10-14 |
2019-07-09 |
Xencor Inc |
proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente
|
|
US10633454B2
(en)
|
2016-11-01 |
2020-04-28 |
Conagen Inc. |
Expression of modified glycoproteins and glycopeptides
|
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
|
AU2017357649A1
(en)
*
|
2016-11-11 |
2019-05-23 |
Autolus Limited |
Chimeric antigen receptor
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
CN117752798A
(zh)
|
2016-12-19 |
2024-03-26 |
豪夫迈·罗氏有限公司 |
用靶向性4-1bb(cd137)激动剂的组合疗法
|
|
MX2019006954A
(es)
|
2016-12-20 |
2019-08-01 |
Hoffmann La Roche |
Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137).
|
|
KR102745676B1
(ko)
|
2016-12-21 |
2024-12-24 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
CN108264561B
(zh)
*
|
2016-12-30 |
2021-09-10 |
惠和生物技术(上海)有限公司 |
一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用
|
|
CN108264559B
(zh)
*
|
2016-12-30 |
2021-08-10 |
惠和生物技术(上海)有限公司 |
一种结合cd19、cd3和t细胞正共刺激分子的三功能分子及其应用
|
|
US11535666B2
(en)
*
|
2016-12-30 |
2022-12-27 |
Cytocares (Shanghai) Inc. |
Trifunctional molecule and application thereof
|
|
CN106589129B
(zh)
*
|
2016-12-30 |
2021-03-05 |
上海近岸生物科技有限公司 |
一种结合cd19、cd3和cd28的三功能分子及其应用
|
|
WO2018120842A1
(zh)
*
|
2016-12-30 |
2018-07-05 |
上海欣百诺生物科技有限公司 |
一种双功能分子及其应用
|
|
DK3579848T3
(da)
|
2017-02-08 |
2025-01-20 |
Dragonfly Therapeutics Inc |
Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft
|
|
US11021535B2
(en)
|
2017-02-10 |
2021-06-01 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
KR20240060739A
(ko)
|
2017-02-20 |
2024-05-08 |
드래곤플라이 쎄라퓨틱스, 인크. |
Her2, nkg2d 및 cd16에 결합하는 단백질
|
|
WO2018178101A1
(en)
*
|
2017-03-27 |
2018-10-04 |
Biomunex Pharmaceuticals |
Stable multispecific antibodies
|
|
SG11201909218RA
(en)
|
2017-04-03 |
2019-11-28 |
Hoffmann La Roche |
Antibodies binding to steap-1
|
|
IL312322B2
(en)
|
2017-06-20 |
2026-05-01 |
Teneobio Inc |
Antibodies against BCMA containing only heavy chains
|
|
WO2018237006A1
(en)
|
2017-06-20 |
2018-12-27 |
Teneoone, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
TWI728250B
(zh)
|
2017-06-21 |
2021-05-21 |
美商基利科學股份有限公司 |
靶向hiv gp120及cd3之多特異性抗體
|
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
EP3652206A1
(en)
|
2017-07-10 |
2020-05-20 |
International-Drug-Development-Biotech |
Treatment of b cell malignancies using afucosylated pro-apoptotic anti-cd19 antibodies in combination with anti cd20 antibodies or chemotherapeutics
|
|
WO2019018538A1
(en)
*
|
2017-07-20 |
2019-01-24 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
RECOMBINANT ANTIBODIES BINDING TO CD123
|
|
CN113896797B
(zh)
|
2017-08-01 |
2023-05-09 |
Ab工作室有限公司 |
双特异性抗体及其用途
|
|
TWI901940B
(zh)
|
2017-08-03 |
2025-10-21 |
美商安進公司 |
介白素-21突變蛋白及治療方法
|
|
US11427826B2
(en)
|
2017-08-11 |
2022-08-30 |
City of Hopw |
RNA aptamers against transferrin receptor (TfR)
|
|
CN111051306B
(zh)
|
2017-09-08 |
2023-01-03 |
美国安进公司 |
Kras g12c的抑制剂及其使用方法
|
|
WO2019051102A2
(en)
|
2017-09-08 |
2019-03-14 |
Maverick Therapeutics, Inc. |
Constrained conditionally activated binding proteins
|
|
EP3694520A1
(en)
|
2017-10-13 |
2020-08-19 |
Merck Sharp & Dohme Corp. |
Compositions and methods for treating diffuse large b cell lymphoma
|
|
CA3079036A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted ox40 agonists
|
|
WO2019091384A1
(en)
*
|
2017-11-08 |
2019-05-16 |
Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. |
Conjugates of biomolecule and use thereof
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
JP2021505637A
(ja)
|
2017-12-12 |
2021-02-18 |
マクロジェニクス，インコーポレーテッド |
二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用
|
|
AU2018390418B2
(en)
|
2017-12-19 |
2023-12-21 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
|
BR112020011469A2
(pt)
|
2017-12-21 |
2020-11-24 |
F. Hoffmann-La Roche Ag |
anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, uso do anticorpo, método de tratamento de uma doença e invenção
|
|
IL275462B2
(en)
|
2017-12-22 |
2026-01-01 |
Genentech Inc |
Targeted integration of nucleic acids
|
|
BR112020013086A2
(pt)
|
2017-12-27 |
2020-12-08 |
Teneobio, Inc. |
Anticorpos específicos de heterodímero de cd3-delta/épsilon
|
|
EP3724223A1
(en)
|
2018-01-02 |
2020-10-21 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
|
JP2019122373A
(ja)
|
2018-01-12 |
2019-07-25 |
アムジエン・インコーポレーテツド |
抗ｐｄ−１抗体及び治療方法
|
|
CN111655730A
(zh)
|
2018-01-31 |
2020-09-11 |
豪夫迈·罗氏有限公司 |
包含与lag3结合的抗原结合位点的双特异性抗体
|
|
EP3746470A1
(en)
|
2018-01-31 |
2020-12-09 |
F. Hoffmann-La Roche AG |
Stabilized immunoglobulin domains
|
|
SG11202007579TA
(en)
|
2018-02-08 |
2020-09-29 |
Dragonfly Therapeutics Inc |
Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
|
|
SG11202007482WA
(en)
|
2018-02-08 |
2020-09-29 |
Dragonfly Therapeutics Inc |
Antibody variable domains targeting the nkg2d receptor
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
SG11202007572VA
(en)
|
2018-02-15 |
2020-09-29 |
Macrogenics Inc |
Variant cd3-binding domains and their use in combination therapies for the treatment of disease
|
|
JP7353576B2
(ja)
|
2018-02-20 |
2023-10-02 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
|
|
CA3091437A1
(en)
|
2018-02-21 |
2019-08-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
CA3092002A1
(en)
|
2018-03-13 |
2019-09-19 |
F. Hoffmann-La Roche Ag |
Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
|
|
JP2021519073A
(ja)
|
2018-03-29 |
2021-08-10 |
ジェネンテック， インコーポレイテッド |
哺乳動物細胞におけるラクトジェニック活性の制御
|
|
AU2019247415A1
(en)
|
2018-04-04 |
2020-10-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
JP2021520829A
(ja)
|
2018-04-18 |
2021-08-26 |
ゼンコア インコーポレイテッド |
ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
AU2019284911B2
(en)
|
2018-06-13 |
2026-04-09 |
Novartis Ag |
BCMA chimeric antigen receptors and uses thereof
|
|
MY208638A
(en)
|
2018-07-02 |
2025-05-21 |
Amgen Inc |
Anti-steap1 antigen-binding protein
|
|
EP3833392A4
(en)
|
2018-08-08 |
2022-05-18 |
Dragonfly Therapeutics, Inc. |
MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
|
|
EP3833385A4
(en)
|
2018-08-08 |
2021-12-22 |
Dragonfly Therapeutics, Inc. |
PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
WO2020052542A1
(en)
|
2018-09-10 |
2020-03-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against cll1 and constructs thereof
|
|
TWI846731B
(zh)
|
2018-09-18 |
2024-07-01 |
瑞士商赫孚孟拉羅股份公司 |
組織蛋白酶(cathepsin)S抑制劑之對抗抗藥抗體形成之用途
|
|
EP3857230B1
(en)
|
2018-09-21 |
2023-06-07 |
F. Hoffmann-La Roche AG |
Diagnostic methods for triple-negative breast cancer
|
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
KR20210090645A
(ko)
|
2018-11-05 |
2021-07-20 |
제넨테크, 인크. |
원핵 숙주 세포에서 2개의 사슬 단백질을 생산하는 방법
|
|
EP3883609A2
(en)
|
2018-12-20 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
|
MX2021007320A
(es)
|
2018-12-21 |
2021-07-07 |
Hoffmann La Roche |
Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor.
|
|
CN113631711B
(zh)
|
2018-12-21 |
2025-03-04 |
豪夫迈·罗氏有限公司 |
核酸的靶向整合
|
|
CN118271445A
(zh)
|
2018-12-21 |
2024-07-02 |
豪夫迈·罗氏有限公司 |
与cd3结合的抗体
|
|
JP7650802B2
(ja)
|
2018-12-30 |
2025-03-25 |
エフ． ホフマン－ラ ロシュ アーゲー |
抗ウサギｃｄ１９抗体および使用方法
|
|
US11098093B2
(en)
*
|
2019-01-07 |
2021-08-24 |
Shattuck Labs, Inc. |
Heterodimeric proteins for modulating gamma delta T cells
|
|
MX2021008561A
(es)
|
2019-01-23 |
2021-08-19 |
Genentech Inc |
Metodos de produccion de proteinas multimericas en celulas huesped eucariotas.
|
|
US12463463B2
(en)
|
2019-01-28 |
2025-11-04 |
Ab Therapeutics, Inc. |
Bispecific antibodies and uses thereof
|
|
WO2020180726A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
WO2020181140A1
(en)
|
2019-03-05 |
2020-09-10 |
Maverick Therapeutics, Inc. |
Constrained conditionally activated binding proteins
|
|
CN109776683B
(zh)
*
|
2019-03-19 |
2020-04-07 |
益科思特(北京)医药科技发展有限公司 |
一种双特异性抗体及其制备方法与应用
|
|
CR20210500A
(es)
|
2019-04-05 |
2021-11-05 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen al psma
|
|
EP3962948A1
(en)
|
2019-04-30 |
2022-03-09 |
Amgen Research (Munich) GmbH |
Means and methods of treating burkitt lymphoma or leukemia
|
|
WO2020227228A2
(en)
|
2019-05-03 |
2020-11-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
BR112021022682A2
(pt)
|
2019-05-14 |
2022-02-22 |
Provention Bio Inc |
Métodos e composições para prevenir diabetes do tipo 1
|
|
CN118994397A
(zh)
|
2019-05-21 |
2024-11-22 |
诺华股份有限公司 |
针对bcma的三特异性结合分子及其用途
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
US12559544B2
(en)
|
2019-05-21 |
2026-02-24 |
University Of Georgia Research Foundation, Inc. |
Antibodies that bind human metapneumovirus fusion protein and their use
|
|
JP7665538B2
(ja)
|
2019-06-14 |
2025-04-21 |
テネオバイオ， インコーポレイテッド |
Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
|
|
AU2020299382A1
(en)
|
2019-07-02 |
2022-01-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind EGFRvIII and their use
|
|
CN119192386A
(zh)
|
2019-07-31 |
2024-12-27 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
|
JP2022543551A
(ja)
|
2019-07-31 |
2022-10-13 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｇｐｒｃ５ｄに結合する抗体
|
|
CN110577603B
(zh)
*
|
2019-08-15 |
2021-12-28 |
北京东方百泰生物科技股份有限公司 |
一种抗cd3和抗cd19双特异性抗体
|
|
AU2020331963A1
(en)
*
|
2019-08-19 |
2022-03-03 |
Elpis Biopharmaceuticals |
Anti-CD19 antibodies and uses thereof
|
|
WO2021041300A2
(en)
*
|
2019-08-23 |
2021-03-04 |
Ab Therapeutics, Inc. |
Bispecific antibodies and uses thereof
|
|
US12312414B2
(en)
|
2019-09-18 |
2025-05-27 |
Genentech, Inc. |
Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
|
|
JP7296467B2
(ja)
|
2019-12-18 |
2023-06-22 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｈｌａ－ａ２／ｍａｇｅ－ａ４に結合する抗体
|
|
PE20221186A1
(es)
|
2019-12-23 |
2022-08-05 |
Genentech Inc |
Anticuerpos especificos de apolipoproteina l1 y metodos de uso
|
|
KR20220140500A
(ko)
|
2020-01-13 |
2022-10-18 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
약물 전달 시스템 성분에 대한 치료제 단백질의 흡착을 방지하기 위한 방법 및 조성물
|
|
WO2021146328A1
(en)
|
2020-01-13 |
2021-07-22 |
Aptevo Research And Development Llc |
Formulations for protein therapeutics
|
|
EP3865513A1
(en)
*
|
2020-02-17 |
2021-08-18 |
Fundación Para La Investigación Biomédica Del Hospital 12 De Octubre |
Anti-cd19/anti-cd3 bispecific antibody, t cells secreting the same, method of preparation and use thereof
|
|
US11896619B2
(en)
|
2020-03-10 |
2024-02-13 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
|
JP2023518841A
(ja)
|
2020-03-26 |
2023-05-08 |
ジェネンテック， インコーポレイテッド |
宿主細胞タンパク質が減少した修飾哺乳動物細胞
|
|
EP4400515A3
(en)
|
2020-04-24 |
2024-10-23 |
F. Hoffmann-La Roche AG |
Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
|
|
IL297601A
(en)
|
2020-04-29 |
2022-12-01 |
Teneobio Inc |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
CN115836088A
(zh)
|
2020-05-06 |
2023-03-21 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和clec12a的蛋白质
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
MX2022015206A
(es)
|
2020-06-08 |
2023-01-05 |
Hoffmann La Roche |
Anticuerpos anti-hbv y metodos de uso.
|
|
US12006366B2
(en)
|
2020-06-11 |
2024-06-11 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
|
MX2022015877A
(es)
|
2020-06-16 |
2023-01-24 |
Genentech Inc |
Metodos y composiciones para tratar cancer de mama triple negativo.
|
|
TWI852680B
(zh)
|
2020-06-19 |
2024-08-11 |
瑞士商赫孚孟拉羅股份公司 |
與 cd3 及 cd19 結合之抗體
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
MX2022015887A
(es)
|
2020-06-19 |
2023-01-24 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y folr1.
|
|
AR122658A1
(es)
|
2020-06-19 |
2022-09-28 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3
|
|
WO2021262783A1
(en)
|
2020-06-24 |
2021-12-30 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
|
EP4172346A1
(en)
|
2020-06-24 |
2023-05-03 |
Genentech, Inc. |
Targeted integration of nucleic acids
|
|
CA3185122A1
(en)
|
2020-07-17 |
2022-01-20 |
Cecilia Pui Chi Chiu |
Anti-notch2 antibodies and methods of use
|
|
EP4185616A1
(en)
*
|
2020-07-24 |
2023-05-31 |
Cellectis S.A. |
T-cells expressing immune cell engagers in allogenic settings
|
|
JP2023536100A
(ja)
*
|
2020-07-27 |
2023-08-23 |
アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ |
代替の翻訳開始および翻訳停止に由来する多機能免疫グロブリンフォールドポリペプチド
|
|
WO2022026772A1
(en)
*
|
2020-07-29 |
2022-02-03 |
Gritstone Bio, Inc. |
Engineered multi-specific antibodies and related methods of use and manufacture
|
|
CA3192204A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
US20240092890A1
(en)
|
2020-08-27 |
2024-03-21 |
Juntendo Educational Foundation |
Anti-cleaved mutant calr-cd3 bispecific antibody and pharmaceutical composition
|
|
CA3192344A1
(en)
|
2020-08-28 |
2022-03-03 |
Genentech, Inc. |
Crispr/cas9 multiplex knockout of host cell proteins
|
|
WO2022109611A1
(en)
|
2020-11-20 |
2022-05-27 |
Simcere Innovation, Inc. |
Armed dual car-t compositions and methods for cancer immunotherapy
|
|
WO2022132904A1
(en)
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
|
CR20230263A
(es)
|
2020-12-17 |
2023-08-21 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de estos
|
|
RS66868B1
(sr)
|
2021-01-28 |
2025-06-30 |
Regeneron Pharma |
Kompozicije i postupci za lečenje sindroma oslobađanja citokina
|
|
WO2022169872A1
(en)
|
2021-02-03 |
2022-08-11 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
|
KR20230152032A
(ko)
|
2021-02-03 |
2023-11-02 |
모차르트 쎄라퓨틱스 인코포레이티드 |
결합제 및 이를 사용하는 방법
|
|
US20240117019A1
(en)
|
2021-02-09 |
2024-04-11 |
University Of Georgia Research Foundation, Inc. |
Human monoclonal antibodies against pneumococcal antigens
|
|
JP2024506315A
(ja)
|
2021-02-09 |
2024-02-13 |
ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
コロナウイルスのスパイクタンパク質を標的とする抗体
|
|
EP4294837A1
(en)
|
2021-02-16 |
2023-12-27 |
Children's Health Care d/b/a Children's Minnesota |
Methods for treating b-all by administering a pre-bcr complex antagonist
|
|
WO2022187539A1
(en)
|
2021-03-03 |
2022-09-09 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
|
|
KR20230156079A
(ko)
|
2021-03-09 |
2023-11-13 |
젠코어 인코포레이티드 |
Cd3과 cldn6에 결합하는 이종이량체 항체
|
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
|
CN117062839A
(zh)
|
2021-03-12 |
2023-11-14 |
基因泰克公司 |
抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体和使用方法
|
|
EP4319820A1
(en)
|
2021-04-10 |
2024-02-14 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
JP2024514222A
(ja)
|
2021-04-19 |
2024-03-28 |
ジェネンテック， インコーポレイテッド |
改変された哺乳動物細胞
|
|
JP7742892B2
(ja)
|
2021-04-23 |
2025-09-22 |
ジェンマブ エー／エス |
抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法
|
|
AU2021443863A1
(en)
|
2021-04-30 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
|
WO2022228705A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
EP4341385A1
(en)
|
2021-05-21 |
2024-03-27 |
Genentech, Inc. |
Modified cells for the production of a recombinant product of interest
|
|
JP2024519964A
(ja)
|
2021-05-21 |
2024-05-21 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
タンパク質治療薬のための投薬レジメン
|
|
WO2022251253A1
(en)
|
2021-05-24 |
2022-12-01 |
Provention Bio, Inc. |
Methods for treating type 1 diabetes
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
US20230197278A1
(en)
|
2021-07-13 |
2023-06-22 |
Genentech, Inc. |
Multi-variate model for predicting cytokine release syndrome
|
|
EP4373859A1
(en)
|
2021-07-22 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Heterodimeric fc domain antibodies
|
|
US20250215103A1
(en)
|
2021-08-03 |
2025-07-03 |
Hoffmann-La Roche Inc. |
Bispecific antibodies and methods of use
|
|
US20240360233A1
(en)
|
2021-08-27 |
2024-10-31 |
Board Of Regents, The University Of Texas System |
Anti-tslpr (crlf2) antibodies
|
|
JP2024535249A
(ja)
|
2021-09-17 |
2024-09-30 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
合成ヒト化ラマナノボディライブラリーおよびｓａｒｓ－ｃｏｖ－２中和抗体を同定するためのその使用
|
|
KR20240099263A
(ko)
|
2021-10-15 |
2024-06-28 |
암젠 리서치 (뮌헨) 게엠베하 |
Cd19 결합 t 세포 관여 항체의 피하 투여
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
WO2023141445A1
(en)
|
2022-01-19 |
2023-07-27 |
Genentech, Inc. |
Anti-notch2 antibodies and conjugates and methods of use
|
|
EP4476251A1
(en)
|
2022-02-10 |
2024-12-18 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Human monoclonal antibodies that broadly target coronaviruses
|
|
US20250161441A1
(en)
|
2022-02-25 |
2025-05-22 |
Juntendo Educational Foundation |
Medicine comprising combination of anti-mutant-calr antibody and another drug
|
|
WO2023180353A1
(en)
|
2022-03-23 |
2023-09-28 |
F. Hoffmann-La Roche Ag |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
|
WO2023192881A1
(en)
|
2022-03-28 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
CN116925234B
(zh)
*
|
2022-04-02 |
2024-05-31 |
合肥星眸生物科技有限公司 |
一种编码抗vegf-a和ang-2双特异性抗体的aav载体
|
|
CA3247475A1
(en)
|
2022-04-11 |
2023-10-19 |
Regeneron Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS FOR THE DESTRUCTION OF UNIVERSAL TUMOR CELLS
|
|
CA3255366A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions based on bispecific anti-CD20/anti-CD3 antibodies and methods of use
|
|
KR20250041021A
(ko)
|
2022-07-22 |
2025-03-25 |
제넨테크, 인크. |
항-steap1 항원 결합 분자 및 이의 용도
|
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
|
WO2024054822A1
(en)
|
2022-09-07 |
2024-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered sars-cov-2 antibodies with increased neutralization breadth
|
|
WO2024064826A1
(en)
|
2022-09-22 |
2024-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
|
|
TW202430211A
(zh)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
|
|
US20260092121A1
(en)
|
2022-10-14 |
2026-04-02 |
Talem Therapeutics Llc |
Anti-trkb/cd3 antibodies and uses thereof
|
|
EP4611903A1
(en)
*
|
2022-11-01 |
2025-09-10 |
TeneoTwo, Inc. |
Methods of treating non-hodgkin lymphoma
|
|
WO2024094741A1
(en)
|
2022-11-03 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Combination therapy with anti-cd19/anti-cd28 bispecific antibody
|
|
KR20250107893A
(ko)
|
2022-11-15 |
2025-07-14 |
제넨테크, 인크. |
숙주 세포로의 트랜스포존 매개 통합 및 핵산의 표적 통합의 조합
|
|
EP4634397A1
(en)
|
2022-12-12 |
2025-10-22 |
Genentech Inc. |
Optimizing polypeptide sialic acid content
|
|
EP4638491A1
(en)
|
2022-12-19 |
2025-10-29 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Monoclonal antibodies for treating sars-cov-2 infection
|
|
WO2024138155A1
(en)
|
2022-12-22 |
2024-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees
|
|
US20240240175A1
(en)
|
2023-01-12 |
2024-07-18 |
Genentech, Inc. |
Combinatorial vector cloning and transfection strategies for targeted integration of nucleic acids
|
|
CN120569410A
(zh)
|
2023-01-25 |
2025-08-29 |
豪夫迈·罗氏有限公司 |
与csf1r和cd3结合的抗体
|
|
JP2026506095A
(ja)
|
2023-02-17 |
2026-02-20 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｃｄ３／ｔａａ二重特異性抗体に応答する誘導ｎｋ細胞
|
|
JP2026510318A
(ja)
|
2023-03-06 |
2026-04-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ＥＧＦＲｖＩＩＩ／抗ＣＤ３抗体と腫瘍標的化４－１ＢＢアゴニストの併用療法
|
|
EP4676951A1
(en)
|
2023-03-10 |
2026-01-14 |
Genentech Inc. |
Fusions with proteases and uses thereof
|
|
WO2024188966A1
(en)
|
2023-03-13 |
2024-09-19 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using an anti-hla-g/anti-cd3 bispecific antibody and a 4‑1bb (cd137) agonist
|
|
CN120936626A
(zh)
|
2023-03-31 |
2025-11-11 |
基因泰克公司 |
抗αvβ8整合素抗体及使用方法
|
|
WO2024231320A1
(en)
|
2023-05-08 |
2024-11-14 |
F. Hoffmann-La Roche Ag |
Targeted interferon alpha fusion proteins and methods of use
|
|
CN121194993A
(zh)
|
2023-05-24 |
2025-12-23 |
莫扎特治疗公司 |
Cd8特异性结合蛋白及其应用方法
|
|
WO2024243355A1
(en)
|
2023-05-24 |
2024-11-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum
|
|
AU2024311339A1
(en)
|
2023-06-21 |
2026-01-08 |
F. Hoffmann-La Roche Ag |
Combination therapy with fap-targeted lymphotoxin beta receptor agonists
|
|
TW202502809A
(zh)
|
2023-06-22 |
2025-01-16 |
美商建南德克公司 |
抗體及其用途
|
|
CN121986113A
(zh)
|
2023-07-07 |
2026-05-05 |
美国政府(由卫生和人类服务部的部长所代表) |
人源化40h3抗体
|
|
WO2025024233A1
(en)
|
2023-07-21 |
2025-01-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific antibodies that broadly target coronaviruses
|
|
CN121712799A
(zh)
|
2023-07-26 |
2026-03-20 |
豪夫迈·罗氏有限公司 |
与cd3结合的抗体
|
|
AR133909A1
(es)
|
2023-09-25 |
2025-11-12 |
Hoffmann La Roche |
ANTICUERPO QUE SE UNE A C3bBb
|
|
WO2025072406A1
(en)
|
2023-09-26 |
2025-04-03 |
Profoundbio Us Co. |
Ptk7 binding agents, conjugates thereof and methods of using the same
|
|
WO2025085705A1
(en)
|
2023-10-18 |
2025-04-24 |
Genentech, Inc. |
Retroviral-like particle-reduced chinese hamster ovary production cell lines
|
|
WO2025106427A1
(en)
|
2023-11-14 |
2025-05-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
|
|
WO2025117639A1
(en)
|
2023-11-27 |
2025-06-05 |
Profoundbio Us Co. |
Antibodies and methods for ptk7 detection
|
|
WO2025117384A1
(en)
|
2023-12-01 |
2025-06-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Broadly neutralizing influenza hemagglutinin stem-directed antibodies
|
|
WO2025125386A1
(en)
|
2023-12-14 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to folr1 and methods of use
|
|
US20260071002A1
(en)
|
2023-12-20 |
2026-03-12 |
Hoffmann-La Roche Inc. |
Antibodies binding to ceacam5
|
|
WO2025137086A1
(en)
|
2023-12-20 |
2025-06-26 |
Genentech, Inc. |
Reducing alpha-gal
|
|
AU2024408954A1
(en)
|
2023-12-21 |
2026-05-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Broadly neutralizing antibodies against sars-cov-2 and sars-cov variants
|
|
WO2025133042A2
(en)
|
2023-12-22 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Activatable fusion proteins and methods of use
|
|
TW202547866A
(zh)
|
2024-01-10 |
2025-12-16 |
丹麥商珍美寶股份有限公司 |
Ｓｌｉｔｒｋ６結合劑、其共軛物及使用彼之方法
|
|
US20250381289A1
(en)
|
2024-02-29 |
2025-12-18 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025181189A1
(en)
|
2024-03-01 |
2025-09-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025181224A1
(en)
|
2024-03-01 |
2025-09-04 |
Amgen Research (Munich) Gmbh |
Cd19-selective t cell engaging molecule for treating autoimmune diseases/ autoimmune conditions
|
|
CN121311509A
(zh)
*
|
2024-04-09 |
2026-01-09 |
艾博生命科学(上海)有限公司 |
Cd3和cd19的结合剂、编码其的核酸及其用途
|
|
WO2025215060A1
(en)
|
2024-04-11 |
2025-10-16 |
F. Hoffmann-La Roche Ag |
Antibodies that specifically bind modified oligonucleotides
|
|
WO2025222129A2
(en)
|
2024-04-19 |
2025-10-23 |
Mozart Therapeutics, Inc. |
Engineered cytokines and targeted cytokine delivery
|
|
WO2025233264A1
(en)
|
2024-05-07 |
2025-11-13 |
Innate Pharma |
Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers
|
|
WO2025233266A1
(en)
|
2024-05-07 |
2025-11-13 |
Innate Pharma |
Use of cd39 blocking agents in combination with anti-cd20 x cd3 t cell engagers
|
|
WO2026006162A2
(en)
|
2024-06-24 |
2026-01-02 |
Genentech, Inc. |
B vitamin modulation
|
|
WO2026030473A1
(en)
|
2024-07-31 |
2026-02-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
West nile virus neutralizing monoclonal antibodies
|
|
WO2026032438A1
(zh)
*
|
2024-08-08 |
2026-02-12 |
惠和生物技术(上海)有限公司 |
多特异性抗体治疗自身免疫性疾病的用途
|
|
WO2026041568A1
(en)
|
2024-08-20 |
2026-02-26 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and dotam
|